← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Gateway Biotechnology, Inc.
St. Louis, MO
$5,345,113
Total funding
9
Grants
Funding over time
peak $1.2M · FY2014–24$2M$1.5M$1M$500K$0
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$5,345,113 · 9
By mechanism
R44$2,179,958 · 1
R42$1,511,899 · 1
R41$1,203,856 · 5
R43$449,400 · 2
Investigators at Gateway Biotechnology, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Emerging Leaders
6–10 yrs in
All-Time
Most funded here, all years
Largest grants
Targeting multiple signaling pathways for tinnitus prevention and treatment$1,207,345
R44 · FY2021 · DC
Targeting multiple signaling pathways for tinnitus prevention and treatment$972,613
R44 · FY2020 · DC
Developing a clinical diagnostic tool for age-related cochlear synaptopathy.$555,803
R42 · FY2022 · AG
Developing a clinical diagnostic tool for age-related cochlear synaptopathy.$482,587
R42 · FY2024 · AG
Developing a clinical diagnostic tool for age-related cochlear synaptopathy.$473,509
R42 · FY2023 · AG
Preclinical Testing of Tetrandrine against Noise-Induce Hearing Loss$224,701
R41 · FY2016 · AT
A new two-drug combination therapy for noise-induced hearing loss$224,700
R43 · FY2014 · DC
Developing a Nutraceutical Product against Noise-Induce Hearing Loss$224,700
R41 · FY2017 · DC
Develop a new cisplatin-based drug combination with reduced ototoxicity$224,700
R41 · FY2017 · DC
An unique patient population for clinical trials against noise-induced hearing loss$224,700
R41 · FY2018 · DC
Developing a new AAV-based tool for targeted gene therapy against hearing loss$224,700
R43 · FY2018 · DC
Developing a Nutraceutical Product against Ototoxicity$205,183
R41 · FY2019 · DC
An unique patient population for clinical trials against noise-induced hearing loss$99,872
R41 · FY2019 · DC